{"nctId":"NCT00678418","briefTitle":"ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence","startDateStruct":{"date":"2008-06"},"conditions":["Opiate Dependence"],"count":250,"armGroups":[{"label":"VIVITROL® 380 mg","type":"EXPERIMENTAL","interventionNames":["Drug: VIVITROL® 380 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"VIVITROL® 380 mg","otherNames":["Naltrexone for extended-release injectable suspension","Medisorb® naltrexone"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Primary Inclusion Criteria:\n\n* Written, informed consent\n* 18 years of age or older\n* Current diagnosis of opioid dependence, based on Diagnostic and Statistical Manual of Mental Health Disorders, 4th Ed. (DSM-IV-TR) criteria\n* Voluntarily seeking treatment for opioid dependence\n* Completing or recently completed up to 30 days of inpatient treatment for opioid detoxification, and off all opioids (including buprenorphine and methadone) for at least 7 days\n* Noncustodial, stable residence and phone, plus 1 contact with verifiable address and phone\n* Significant other (eg, spouse, relative) willing to supervise compliance with the study visit schedule and procedures\n* Agree to use contraception for study duration if of childbearing potential\n\nPrimary Exclusion Criteria:\n\n* Pregnancy or lactation\n* Clinically significant medical condition or observed abnormalities (eg: physical exam, electrocardiogram (ECG), lab and/or urinalysis findings)\n* Positive naloxone challenge test at randomization (Day 0)\n* Evidence of hepatic failure including: ascites, bilirubin \\>10% above upper limit of normal (ULN) and/or esophageal variceal disease\n* Past or present history of an acquired immunodeficiency syndrome (AIDS)-indicator disease in HIV-infected subjects\n* Active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase(ALT) \\>3xULN\n* Current major depression with suicidal ideation, psychosis, bipolar disorder, or any psychiatric disorder that would compromise ability to complete the study\n* Recent history (within 6 months prior to screening) of suicidal ideation or attempt\n* Dependence within prior year based on DSM-IV-TR, to any drugs other than prescription opioids or heroin, caffeine, marijuana, or nicotine\n* Active alcohol dependence within prior 6 months\n* Current alcohol use disorder that would, in the Investigator's opinion, preclude successful completion of the study\n* Positive urine drug test for cocaine, benzodiazepines, or amphetamines at screening\n* Use of oral naltrexone for 7 consecutive days within 60 days prior to screening\n* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A)","description":"Included are data from the last 20 weeks of the 24-week double-blind treatment period (Part A). Response profiles for each Arm are based on subjects' individual rates of weekly opioid-free data, including negative urine test results, attendance at study visits, and self-reports of opioid use/non-use.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":"40.1"},{"groupId":"OG001","value":"35.0","spread":"43.3"}]}]}]},{"type":"SECONDARY","title":"Days to Discontinuation During Part A","description":"Defined as the duration of study participation and calculated as the number of days from Dose 1 to the day of study discontinuation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Craving Score: Change From Baseline","description":"Measured using subjects' response on a validated Visual Analog Scale at prespecified weekly visits throughout Part A, with comparison of baseline to end of Part A. The scale ranged from 0 (\"No craving\") to 100 (\"highest possible craving\").","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.087","spread":null},{"groupId":"OG001","value":"0.654","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Subjects Who Relapsed to Physiologic Opioid Dependence During the 24-week Treatment Period (Part A)","description":"Assessment of relapse to physiologic opioid dependence was based on individual subjects' results on the naloxone challenge test. A positive naloxone challenge test result was considered as a relapse to physiologic opioid dependence.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null},{"groupId":"OG001","value":"62.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Percentage of Self-reported Opioid-free Days From Baseline to Week 24","description":"Opioid use was measured using subjects' entries on a validated Timeline FollowBack (TLFB) calendar in which they recorded their use/non-use of opioids each day.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.83","spread":null},{"groupId":"OG001","value":"46.43","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":126},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Gamma-glutamyl transferase increased","Nasopharyngitis","Influenza"]}}}